4.1 Article

The VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention (VITAL-DEP): Rationale and design of a large-scale ancillary study evaluating vitamin D and marine omega-3 fatty acid supplements for prevention of late-life depression

Journal

CONTEMPORARY CLINICAL TRIALS
Volume 68, Issue -, Pages 133-145

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.cct.2018.02.017

Keywords

Geriatric; Depression; Mood; Prevention; Cholecalciferol; Fish oil; Omega-3

Funding

  1. NIMH [R01 MH091448, P30 MH090333]
  2. National Cancer Institute of National Institutes of Health (NIH) [U01 CA138962, R01 CA138962]
  3. National Heart, Lung and Blood Institute (NHLBI) of National Institutes of Health (NIH)
  4. Office of Dietary Supplements of National Institutes of Health (NIH)
  5. National Institute of Neurological Disorders and Stroke of National Institutes of Health (NIH)
  6. National Center for Complementary and Alternative Medicine of National Institutes of Health (NIH)
  7. National Institute of Diabetes and Digestive and Kidney Diseases [DK088078, R01 DK088762]
  8. NHLBI [R01 HL101932, R01 HL102122]
  9. National Institute on Aging (NIA) [R01 AG036755]
  10. National Institute of Arthritis and Musculoskeletal and Skin Diseases [R01 AR059086, R01 AR060574]
  11. National Institute of Mental Health (NIMH) [R01 MH091448]
  12. University of Pittsburgh Medical Center Endowment in Geriatric Psychiatry

Ask authors/readers for more resources

Rationale: Depression is a leading cause of disease burden and disability for older adults; thus, prevention is a priority. Biologic and observational data support potential mental health benefits of vitamin D and omega-3 fatty acids; however, it is unclear whether these supplements can prevent late-life depression. Design: We describe the novel methodology of a large-scale study: VITAL-DEP (VITamin D and OmegA-3 TriaL-Depression Endpoint Prevention), an ancillary to the VITAL trial. Primary Aims of VITAL-DEP are to determine effects on prevention of depression and on trajectory of mood symptoms of long-term (mean = 5 years) supplementation with vitamin D (vitamin D3 [cholecalciferol], 2000 IU/day) and marine omega-3 fatty-acids (eicosapentaenoic acid + docosahexaenoic acid, 1 g/day), in a 2 x 2 factorial design, among 25,874 older adults. Secondary Aims will evaluate: vitamin D's effects among African-Americans (an at-risk group for vitamin D deficiency); both agents' effects among those with high-risk factors or sub-syndromal depression in a sub-set of similar to 1000 participants with detailed examinations at baseline and 2-year follow-up; whether baseline nutrient levels influence depression risk and/or modify agents' effects. Additional planned analyses will use pre-randomization blood samples available in similar to 17,000 participants to address whether key blomarkers and factors influence long-term mood and depression risk and/or the agents' effects. Conclusion: VITAL-DEP applies all modalities of state-of-the-art prevention research -universal, selective and indicated. VITAL-DEP will clarify effects of supplemental vitamin D and/or omega-3 on mood, and inform clinical care and public health guidelines on the use of these agents for prevention of depression in mid-life and older adults.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available